Trials / Recruiting
RecruitingNCT04765098
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
A Randomized Controlled Trial of Tamoxifen Versus Etoposide for Patients With First Recurrence of Glioblastoma Multiforme
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- AHS Cancer Control Alberta · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tamoxifen | Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously |
| DRUG | Etoposide | etoposide 50mg/m2 daily |
Timeline
- Start date
- 2022-01-28
- Primary completion
- 2026-12-01
- Completion
- 2027-07-01
- First posted
- 2021-02-21
- Last updated
- 2025-06-26
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04765098. Inclusion in this directory is not an endorsement.